Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Strongbridge Biopharma

Request full access

Acquired biopharma developing therapies for rare diseases

United StatesFounded 1996Biotech & Life Sciences

About Strongbridge Biopharma

Strongbridge Biopharma was a global, commercial-stage biopharmaceutical company focused on developing and marketing therapies for rare diseases with significant unmet needs. The company was founded in 1996 by Per Marin.

In May 2021, Xeris Pharmaceuticals, Inc. announced a definitive agreement to acquire Strongbridge Biopharma in a stock and contingent value rights (CVRs) transaction valued at approximately $267 million. The acquisition was completed in October 2021, and the combined businesses began operating under a new entity named Xeris Biopharma Holdings, Inc. Following the acquisition, former Strongbridge shareholders owned approximately 40% of the new entity, with former Xeris shareholders owning the remaining 60%. John H. Johnson, the former CEO of Strongbridge, joined the Board of Directors of Xeris Biopharma Holdings.

Prior to the acquisition, Strongbridge's portfolio included a rare endocrine franchise and a rare neuromuscular franchise. The main product in the neuromuscular franchise was KEVEYIS® (dichlorphenamide), the first and only FDA-approved treatment for primary periodic paralysis. The endocrine franchise was centered on RECORLEV® (levoketoconazole), a cortisol synthesis inhibitor for treating endogenous Cushing's syndrome, which was under FDA review at the time of the acquisition. The acquisition was intended to create a more diversified biopharmaceutical company with multiple revenue streams and a robust pipeline, combining Xeris' Gvoke® with Strongbridge's KEVEYIS® and the anticipated launch of RECORLEV®.

Source: Dealroom company data

At a glance

Status
Listed
Founded
1996
Headquarters
United States
Listing
IPO 2015
Sector
Biotech & Life Sciences
Outcome tier
Colt$25–100M revenue

Strongbridge Biopharma in its local ecosystem

Live from Dealroom

The Strongbridge Biopharma office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

5 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series B and later5 investors entered at this stage

Team profiled 9 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States HQ
Book a demo for the full country breakdown
Web traffic by country
250 monthly visits
across markets
🇺🇸 United States280%
Top 1 markets shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Strongbridge Biopharma on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Strongbridge Biopharma on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.